ArticleOncology letters2019
Curcumin-induced promoter hypermethylation of the mammalian target of rapamycin gene in multiple myeloma cells.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Mechanistic and translational insights into plant-derived natural products in preclinical multiple myeloma research: Current evidence.Translational oncology · 2026Review
- Curcumin: biochemistry, pharmacology, advanced drug delivery systems, and its epigenetic role in combating cancer.Frontiers in pharmacology · 2025Review
- Polyphenols bind G4-Quadruplex structures and act as epigenetic modifiers with anti-cancer effects.EXCLI journal · 2025Review
- Curcumin in treatment of hematological cancers: Promises and challenges.Journal of traditional and complementary medicine · 2024Review
- Conceptualizing an Integrative Multiple Myeloma Care: The Role of Nutrition, Supplements, and Complementary Modalities.Nutrients · 2024Review
- Expression of mTOR in normal and pathological conditions.Molecular cancer · 2023Review
- The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.Biomolecules · 2022Review
- Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment.International journal of molecular sciences · 2022Review
- Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions.Frontiers in pharmacology · 2022Review
- Memorable Food: Fighting Age-Related Neurodegeneration by Precision Nutrition.Frontiers in nutrition · 2021Review
- Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.Oncology reports · 2020Article
- The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.Frontiers in oncology · 2020Review
- Natural Products Impacting DNA Methyltransferases and Histone Deacetylases.Frontiers in pharmacology · 2020Review
- Target of Rapamycin Regulates Genome Methylation Reprogramming to Control Plant Growth inFrontiers in genetics · 2020Article
- CpG and Non-CpG Methylation in the Diet-Epigenetics-Neurodegeneration Connection.Current nutrition reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcumin, a polyphenol derived from the rhizome of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.